Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA’s Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia..Up an down..we are looking at a Massive Future Winner..
MY DD..AND OPINIONS SHOULD NOT BE TAKEN SERIOUSLY..THEY ARE SUBJECT TO A LOT OF ERRORS..TRADE WISELY..TRUST ..NO ONE..ITS A MAD..BAD WORLD OUT THERE..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.